Voxelotor is a hemoglobin modulator approved for the treatment of sickle cell disease. It works by increasing hemoglobin's affinity for oxygen, which helps inhibit the polymerization of sickled hemoglobin and thereby reduces hemolysis and anemia. Voxelotor improves hemoglobin levels and reduces markers of hemolytic activity. It represents a disease-modifying treatment that targets the root cause of sickling in red blood cells.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Voxelotor and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Voxelotor impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Voxelotor-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
